BHV 8555
Alternative Names: BHV-8555Latest Information Update: 03 Apr 2026
At a glance
- Originator Biohaven Labs
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Alpha-synuclein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Parkinson's disease